| Feb 1, 2024 | BioAge Labs | $170.0M Series D | Sofinnova Investments | F-Prime Capital Partners, Highbury Group, Johnson & Johnson Innovation, Third Rock Ventures, Uprising, VZVC, Amgen Ventures, Bio + Health, Cormorant Asset Management, Patrick Enright, OrbiMed, Osage University Partners, Pivotal bioVenture Partners, RA Capital Management, RTW Investments, Sands Capital, SV Health Investors |
| Jul 1, 2018 | Sutro Biopharma | $85.0M Series E | Samsara BioCapital, Surveyor Capital | Advent Life Sciences, Alta Partners, Amgen Ventures, Celgene, Eventide Asset Management, Merck, Nexthera Capital, Skyline Ventures, SV Health Investors, Tekla Capital Management, Vida Ventures |
| Jun 5, 2018 | Nimbus Therapeutics | $65.0M Other Equity | — | Bill Gates, Bruce Booth, Lightstone Ventures, Schr"dinger, SR One |
| Oct 1, 2017 | Kymera Therapeutics | $30.0M Series A | Atlas Venture | Novartis Venture Fund, SR One, Wellington Partners, Amgen Ventures, Steve Hall |
| Jan 6, 2017 | Cavion | $26.1M Series A | Sergei Petukhov, Steve Hall, Henry Skinner | — |
| Dec 1, 2015 | Symic Biomedical | $25.0M Series A | Armen Shanafelt | — |
| Jul 1, 2015 | Protagonist Therapeutics | $40.0M Series C | Canaan Partners | Adage Capital Management, Foresite Capital, Johnson & Johnson Innovation, Pharmstandard International, RA Capital Management, Starfish Ventures |
| Apr 14, 2015 | Innocrin Pharmaceuticals | $28.0M Series D | Fred Eshelman | A&B Equity Holdings, Hatteras Venture Partners, Intersouth Partners, Novartis |
| Mar 1, 2015 | Nimbus Therapeutics | $43.0M Series B | Ralph "Chris" Christoffersen | 10100, Access Biotechnology, ARCH Venture Partners, Atlas Venture, Browder Capital, Gigafund, Krishna Yeshwant, NEO, Pfizer Venture Investments, RA Capital, Sanofi Ventures, SR One, Trucks Venture Capital, Bill Gates, Emil Michael, Bill Gates |
| Mar 1, 2015 | Aeglea BioTherapeutics | $44.0M Series B | Armen Shanafelt, Novartis | RA Capital, Ally Bridge Group, Cowen Healthcare Investments, Jennison Associates, OrbiMed, Rajeev Shah, Rock Springs Capital, UT Horizon Fund, Venrock |
| Feb 1, 2015 | Lysosomal Therapeutics | $20.0M Series A | Atlas Venture | Advent Life Sciences, Apollo Health Ventures, ARCH Venture Partners, Hatteras Venture Partners, Omega Funds, Polaris Partners, Red Tree Venture Capital, Roche Venture Fund, Vivo Capital, Bob Carpenter, Henri Termeer, Orion Equity Partners, Partners Innovation Fund, Roche, Sanofi Ventures |
| Jan 5, 2015 | Symic Biomedical | $15.0M Series A | Armen Shanafelt | Ally Bridge Group, Claus Christiansen, InCube Ventures, Mission Bay Capital, Mitsui & Co. Global Investment, Purdue Research Foundation, QB3 Partners |
| Jan 1, 2015 | Surface Oncology | $35.0M Series A | Atlas Venture, Robert Weisskoff, Armen Shanafelt, Robert Garland | Elliott Sigal, Amgen Ventures, Novartis Institutes for Biomedical Research |
| Oct 1, 2014 | Aileron Therapeutics | $33.0M Series E | AJU IB Investment | Abingworth, ATP (Apple Tree Partners), Apple Tree Partners, Excel Venture Management, Novartis, Roche, SR One |
| Oct 1, 2014 | Viamet Pharmaceuticals | $60.0M Series D | Adrian Howd, Woodford Investment Management | Hatteras Venture Partners, Astellas Venture Management, Intersouth Partners, Lurie Investments, Novartis |
| May 1, 2014 | Lysosomal Therapeutics | $5.0M Seed | Atlas Venture | Advent Life Sciences, Apollo Health Ventures, ARCH Venture Partners, Hatteras Venture Partners, Omega Funds, Polaris Partners, RA Capital, Red Tree Venture Capital, Roche Venture Fund, Vivo Capital, Steve Hall, Orion Equity Partners, Reza Halse, Carole Nuechterlein, Bernard Davitian |
| May 1, 2014 | Coherus Biosciences | $55.0M Series C | — | Acorn Bioventures, F-Prime Capital, Ali Satvat, RA Capital Management, Rock Springs Capital, Sofinnova Ventures, Venrock, Vivo Capital |
| Dec 11, 2013 | Sutro Biopharma | $26.0M Series D | — | Alta Partners, Amgen Ventures, Celgene, Skyline Ventures, SV Health Investors |
| Nov 1, 2013 | Aileron Therapeutics | $30.0M Series E | — | Abingworth, ATP (Apple Tree Partners), Apple Tree Partners, Excel Venture Management, Novartis, Roche, SR One |
| Apr 1, 2012 | Sutro Biopharma | $8.0M Series C | Leon Chen | Endeavor Venture Funds, Alta Partners, Amgen Ventures, SV Health Investors |
| Feb 22, 2012 | Bristol-Myers Squibb | $50.0M Other Equity | Polaris Partners | ARCH Venture Partners, Flagship Ventures, Venrock |
| Dec 1, 2011 | Cerulean Pharma | $15.0M Series D | — | Abingworth, Advanced Technology Ventures, ARCH Venture Partners, Lightspeed Venture Partners, Longwood Fund, Polaris Partners, Venrock, Bessemer Venture Partners, CVF, Robert Paull, Polaris Partners |
| Jun 1, 2011 | Nimbus Therapeutics | $24.0M Series A | Atlas Venture, Steve Hall, Kent Gossett | 10100, Access Biotechnology, Browder Capital, Gigafund, NEO, Sanofi Ventures, Trucks Venture Capital, Emil Michael, Bill Gates |
| Nov 17, 2010 | Sutro Biopharma | $36.5M Series C | Skyline Ventures | Alta Partners, Amgen Ventures, Armen Shanafelt, SV Health Investors |
| Nov 1, 2010 | Cerulean Pharma | $24.0M Series C | Steve Hall | Abingworth, Advanced Technology Ventures, ARCH Venture Partners, Lightspeed Venture Partners, Longwood Fund, Polaris Partners, Venrock, Bessemer Venture Partners, Lux Capital, Polaris Partners |
